引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 68次   下载 13 本文二维码信息
码上扫一扫!
胸腺肽联合标准化方案对难治性耐多药肺结核患者血清MMP 9和sTREM 1表达的影响
陈瑞华,谢婷,贾钦尧
0
(重庆三峡中心医院;川北医学院药学院药物研究所)
摘要:
【摘要】目的 观察胸腺肽联合标准方案治疗难治性耐多药肺结核(MDRTB)的临床疗效及其对患者血清中MMP9及sTREM1水平的影响。方法 选取2014年1月~2015年10月于重庆三峡中心医院就诊的MDRTB的患者230例,按照随机数字表法分为对照组和研究组,每组各115例。对照组给予6ZVAmPtoPAS/18 ZVPtoPAS治疗;研究组给予6ZVAmPtoPASCS+胸腺肽/18 ZVPtoPASCS治疗。两组患者在服药期间均加用葡醛内酯片行保肝治疗。观察两组患者的临床疗效,不良反应发生率,测量血清MMP9及sTREM1水平。结果 研究组治愈率明显高于对照组(P<005)。治疗前,两组患者血清中MMP9及sTREM1水平比较差异无统计学意义(P>005);治疗后,两组患者血清中MMP9及sTREM1水平均明显下降,研究组下降程度大于对照组(P<005)。两组不良反应发生率比较差异无统计学意义(P>005)。结论 胸腺肽联合6VZthKP/18VZthP治疗对难治性耐多药肺结核患者的疗效较好,可显著提高患者免疫力,改善患者预后,降低其炎症反应,且无严重不良反应发生,可在临床推广。
关键词:  胸腺肽  耐多药肺结核  MMP 9  sTREM 1
DOI:
基金项目:重庆市卫计委课题 (ZY201703067)
Effect of thymosin combined with standardized regimen on serum MMP 9, sTREM 1 expression in patients with refractory multidrug resistant pulmonary tuberculosis
CHEN Ruihua,XIE Ting,JIA Qinyao
(Chongqing Three Gorges Center Hospital;Institute of medicine, School of pharmacy, North Sichuan Medical College)
Abstract:
【Abstract】Objective To observe the clinical efficacy of thymosin combined with standard regimen in the treatment of refractory pulmonary tuberculosis and its effect on serum MMP9 and sTREM1 levels.Methods Two hundred and thirty patients with MDRTB from January 2014 to October 2015 were randomly divided into control group and study group with 115 cases in each group. The control group was treated with 6ZVAmPtoPAS/18 ZVPtoPAS and the study group with 6ZVAmPtoPASCS thymosin / 18 ZVPtoPASCS. The clinical efficacy, incidence of adverse reactions and serum MMP9 and sTREM1 levels were observed in the two groups.The patients in both groups were treated with gluconolactone tablets during the treatment period.Results The cure rate of the study group was significantly higher than that of the control group (P<005). Before treatment, there was no significant difference in serum MMP9 and sTREM1 levels between the two groups (P>005). After treatment, the serum levels of MMP9 and sTREM1 in the two groups were significantly decreased, but the degree of decrease in the study group was significantly higher than that in the control group (P<005). There was no significant difference in the incidence of adverse reactions between the two groups (P>005). Conclusion Thymosin combined with 6VZthKP/18VZthP has a better effect on patients with refractory pulmonary tuberculosis. It can significantly improve the immunity of patients, improve the prognosis of patients, reduce their inflammatory reaction, and there is no serious adverse reaction, so it is worth popularizing in clinic.
Key words:  Thymosin  Refractory pulmonary tuberculosis  MMP 9  TREM 1

用微信扫一扫

用微信扫一扫